United States - English - NLM (National Library of Medicine)

mad beauty usa llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - reduce bacteria on hands.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

propharma medical supplies palestinian territory - 30g aluminium tube - cream - 5% - n/a

Australia - English - Department of Health (Therapeutic Goods Administration)

moogoo skin care pty ltd - aloe vera,centella asiatica,matricaria chamomilla,sage oil dalmatian -

Australia - English - Department of Health (Therapeutic Goods Administration)

moogoo skin care pty ltd - centella asiatica, quantity: 10 mg/g (equivalent: centella asiatica, qty 5 mg/g); sage oil dalmatian, quantity: 0.5 mg/g (equivalent: thujone, qty 0.15 mg/g); matricaria chamomilla, quantity: 10 mg/g (equivalent: matricaria chamomilla, qty 5 mg/g); aloe vera, quantity: 2 mg/g (equivalent: aloe vera, qty 20 mg/g) - cream - excipient ingredients: piroctone olamine; humulus lupulus; olive oil; cetostearyl alcohol; allantoin; polysorbate 60; citric acid; purified water; xanthan gum; squalane; almond oil; d-alpha-tocopheryl acetate - anti-inflammatory/relieve inflammation ; decrease/reduce/relieve symptoms of mild eczema/dermatitis ; decrease/reduce/relieve symptoms of mild psoriasis ; decrease/reduce/relieve skin dryness ; soothe skin ; decrease/reduce/relieve skin scaling/crusty skin ; helps reduce occurrence of skin dryness ; decrease/reduce/relieve symptoms of mild, superficial skin fungal infections ; soothe/relieve skin inflammation ; decrease/reduce/relieve skin irritation ; antipruritic/relieves itchy skin ; decrease/reduce/relieve skin redness ; relieve red skin rash ; helps enhance/promote skin health ; maintain/support skin health ; enhance/improve/promote skin healing ; maintain/support wound healing ; maintain/support skin repair/healing/regeneration

Israel - English - Ministry of Health

astrazeneca (israel) ltd - aclidinium as bromide; formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 11.8 mcg; aclidinium as bromide 340 mcg - aclidinium bromide - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 190mg;   - modified release tablet - 190 mg - active: metoprolol succinate 190mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 47.5mg;   - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 95mg;   - modified release tablet - 95 mg - active: metoprolol succinate 95mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 23.75mg;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

Israel - English - Ministry of Health

megapharm ltd - rifaximine - film coated tablets - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria.• non-complicated diverticular diseases.